Thomas joined PTC in March 2020, continuing his career in the biopharmaceutical industry, having held positions for Amgen, Merck, Biogen and, most recently, at the global association, DIA. He has worked in the interconnected areas of market access, government affairs, public affairs, health policy, corporate communications, and patient advocacy. In each role, Thomas has spearheaded initiatives that are crucial to bringing much-needed medicines to patients. Throughout his career, Thomas has advised and represented companies, as well as industry federations in engagements with policy makers, patient representatives, media, regulators, payers, and other national and European health policy platforms. Thomas is a board member of Europabio since June 2022. In the past he held other board positions at several European associations, such as Europabio and EUCOPE, chaired a variety of working groups related to regulatory and access issues within EFPIA, and has been a member of the European Commission High Level Pharmaceutical Forum (2005-2008) and its Process on Corporate Responsibility in the Field of Pharmaceuticals (2010-2012).